← Browse by Condition
Medical Condition
marginal zone lymphoma
Total Trials
5
Recruiting Now
5
Trial Phases
Phase 1, Phase 2, Phase 2
Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.
Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.
Frequently Asked Questions — marginal zone lymphoma Clinical Trials
How many clinical trials are currently recruiting for marginal zone lymphoma?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for marginal zone lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for marginal zone lymphoma?
marginal zone lymphoma research spans Phase 1 (1 trial), Phase 2 (5 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a marginal zone lymphoma clinical trial?
Eligibility criteria for marginal zone lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 1
Phase 2 5
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06533579 Phase 1, Phase 2
Recruiting
Enrollment
32 pts
Location
United States
Sponsor
Vironexis Biotherapeutics Inc.
NCT06300528 Phase 2
Recruiting
Enrollment
27 pts
Location
United States
Sponsor
University of Utah
NCT06796998 Phase 2
Recruiting
Enrollment
25 pts
Location
United States
Sponsor
Izidore Lossos, MD
NCT05805605 Phase 2
Recruiting
Enrollment
56 pts
Location
United States
Sponsor
Masonic Cancer Center, Univers...
NCT06566807 Phase 2
Recruiting
Enrollment
51 pts
Location
China
Sponsor
Huai'an First People's Hospita...
Related Conditions
small lymphocytic lymphoma (2) follicular lymphoma (2) mantle cell lymphoma (2) burkitt lymphoma (2) b cell acute lymphoblastic leukemia (1) large b cell lymphoma (1) chronic lymphocytic leukemia (1) diffuse large b cell lymphoma (1) high grade b cell lymphoma (1) primary mediastinal large b cell lymphoma pmbcl (1) non hodgkin lymphoma (1) mixed phenotype acute leukemia (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology